UK Markets open in 6 hrs 57 mins

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3070-0.0299 (-8.88%)
At close: 04:00PM EDT
0.3073 +0.00 (+0.10%)
After hours: 04:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3369
Open0.3370
Bid0.3074 x 800
Ask0.3300 x 38500
Day's range0.2910 - 0.3370
52-week range0.2910 - 11.0000
Volume145,003
Avg. volume360,345
Market cap4.739M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.2410
Earnings date29 Mar 2022 - 04 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

    HOUSTON, May 13, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces financial results for the first quarter ended March 31, 2022.

  • Business Wire

    Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

    HOUSTON, May 11, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the Company will submit an amended Investigational New Drug Application (IND) for its first oncology cell therapy candidate Procel™ directly to the FDA in t

  • Business Wire

    Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation

    HOUSTON, April 11, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company’s most recent corporate presentation. The updated presentation can be accessed on the investor relations sec